Ono Entered into a Multi Target R&D Collaboration Agreement with PrecisionLife to Identify Novel Therapeutic Targets
Shots:
- The collaboration utilizes PrecisionLife’s combinatorial analytics-generated insights to identify novel therapeutic targets & patient stratification biomarkers for CNS disorders to be developed by Ono
- The collaboration strengthens PrecisionLife’s precision medicine & drug discovery capabilities & provides rights to Ono to select targets with genetic validation, mechanistic hypotheses, preclinical validation, and patient stratification biomarkers to optimize the clinical development of the assets
- Ono also obtains the global rights to develop & commercialize a pharmaceutical product acting on the target. PrecisionLife has analyzed ~40 high-value disease indications & maintains a deep portfolio of insights and patented discoveries in its DiseaseBank repository
Ref: Ono | Image: Ono
Click here to read the full press release